Brokers Offer Predictions for Trevi Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:TRVI)

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Trevi Therapeutics in a note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($0.11) for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.47) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.10) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same period in the prior year, the company earned ($0.07) EPS.

Several other brokerages have also issued reports on TRVI. Rodman & Renshaw initiated coverage on Trevi Therapeutics in a research report on Thursday, June 13th. They issued a “buy” rating and a $7.00 price objective for the company. HC Wainwright began coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set a “buy” rating and a $6.00 price objective for the company. EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Raymond James assumed coverage on Trevi Therapeutics in a research report on Friday, August 30th. They issued an “outperform” rating and a $9.00 target price on the stock. Finally, Leerink Partners started coverage on shares of Trevi Therapeutics in a research note on Monday. They set an “outperform” rating and a $7.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Trevi Therapeutics currently has a consensus rating of “Buy” and an average target price of $7.67.

Trevi Therapeutics Trading Up 4.8 %

NASDAQ:TRVI opened at $3.30 on Tuesday. The stock has a market cap of $239.55 million, a price-to-earnings ratio of -9.71 and a beta of 0.96. The stock has a 50-day moving average price of $2.89 and a two-hundred day moving average price of $2.88. Trevi Therapeutics has a 1 year low of $0.97 and a 1 year high of $4.00.

Institutional Trading of Trevi Therapeutics

Hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. lifted its position in Trevi Therapeutics by 7.3% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock worth $9,891,000 after acquiring an additional 500,000 shares during the last quarter. Logos Global Management LP lifted its holdings in shares of Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after buying an additional 600,000 shares in the last quarter. Opaleye Management Inc. lifted its holdings in shares of Trevi Therapeutics by 4.3% during the first quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company’s stock worth $9,125,000 after buying an additional 110,000 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Trevi Therapeutics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after acquiring an additional 60,249 shares during the period. Finally, Ally Bridge Group NY LLC bought a new position in Trevi Therapeutics during the second quarter worth about $4,395,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.76, for a total value of $51,501.60. Following the sale, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the transaction, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. The disclosure for this sale can be found here. Insiders have sold 40,355 shares of company stock valued at $116,663 in the last 90 days. 24.37% of the stock is currently owned by insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.